PMID- 28730788
OWN - NLM
STAT- MEDLINE
DCOM- 20190712
LR  - 20190712
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 22
IP  - 3
DP  - 2017 May-Jun
TI  - Topoisomerase I deregulation in laryngeal squamous cell carcinomas based on 
      tissue microarray analysis.
PG  - 771-776
AB  - PURPOSE: Topoisomerases (types: I/IIa-b/IIIa-b) represent a super-family of 
      nucleic enzymes involved in the DNA replication, transcription, recombination, 
      and also chromosome topological formation. Topoisomerase's I (Topo I- gene 
      location: 20q12) aberrant expression is a frequent genetic event in a variety of 
      solid malignancies. Topo I inhibition promotes cell death due to DNA damage and 
      for this reason it is a target for specific targeted chemotherapy (camptothecin, 
      topotecan, irinotecan). Our aim was to investigate the role of abnormal Topo I 
      protein expression in laryngeal squamous cell carcinomas (LSCC) in which there 
      are very limited data regarding the influence of the marker. METHODS: Using 
      tissue microarray (TMA) technology, 50 formalin-fixed, paraffin-embedded primary 
      laryngeal SCCs were cored and re-pembedded into one recipient block. 
      Immunohistochemistry was performed using anti- Topo I antibody. Digital image 
      analysis was also implemented for evaluating objectively the protein expression 
      levels on the corresponding stained nuclei. RESULTS: Topo I protein 
      overexpression (moderate to high staining intensity values) was observed in 32/50 
      (64%) tissue cores, whereas low expression rates were detected in 18/50 (36%) 
      cases. Topo I overall expression was strongly associated with the differentiation 
      grade of the examined tumors (p=0.021). No other statistical correlations were 
      identified. CONCLUSIONS: Topo I overexpression is observed in a significant 
      subset of LSCCs affecting the level of differentiation in them. Additional 
      molecular studies focused on the mechanism of Topo I gene/protein deregulation 
      (i.e. amplification, abnormal epigenetic promoter methylation, mRNA aberrant 
      expression) are necessary discriminating the eligible patients for applying 
      specific chemotherapeutic strategies based on anti-Topo I agents.
FAU - Papadas, Theodoros A
AU  - Papadas TA
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Medical School, 
      University of Patras; Patras, Greece.
FAU - Tsiambas, Evangelos
AU  - Tsiambas E
FAU - Mastronikolis, Nicholas S
AU  - Mastronikolis NS
FAU - Karameris, Andreas
AU  - Karameris A
FAU - Mastronikolis, Stylianos N
AU  - Mastronikolis SN
FAU - Papadas, Athanasios T
AU  - Papadas AT
FAU - Fotiades, Panagiotis P
AU  - Fotiades PP
FAU - Ragos, Vasileios
AU  - Ragos V
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - EC 5.99.1.2 (DNA Topoisomerases, Type I)
SB  - IM
MH  - DNA Topoisomerases, Type I/analysis/genetics/*physiology
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/*enzymology
MH  - Male
MH  - Squamous Cell Carcinoma of Head and Neck/*enzymology
MH  - Tissue Array Analysis/*methods
EDAT- 2017/07/22 06:00
MHDA- 2019/07/13 06:00
CRDT- 2017/07/22 06:00
PHST- 2017/07/22 06:00 [entrez]
PHST- 2017/07/22 06:00 [pubmed]
PHST- 2019/07/13 06:00 [medline]
PST - ppublish
SO  - J BUON. 2017 May-Jun;22(3):771-776.